EAM
LENZ

Erste Asset Management’s LENZ Therapeutics LENZ Stock Holding History

Erste Asset Management’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,700
Closed -$30.8K – 589
2023
Q2 		$30.8K Hold
1,700
– – ﹤0.01% 549
2023
Q1 		$28.7K Hold
1,700
– – ﹤0.01% 567
2022
Q4 		$38.3K Hold
1,700
– – ﹤0.01% 548
2022
Q3 		$36.5K Hold
1,700
– – ﹤0.01% 538
2022
Q2 		$33.3K Hold
1,700
– – ﹤0.01% 554
2022
Q1 		$61K Buy
+1,700
New +$106K ﹤0.01% 528

Other funds holding LENZ

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Erste Asset Management's LENZ Position: Q3 2023 in Review

Erste Asset Management sold out of LENZ Therapeutics (LENZ) in Q3 2023, closing a stake of 1,700 shares — an estimated $30.8K sold.

Erste Asset Management first reported a position in LENZ in Q1 2022 and held it in 6 quarters. The position peaked at $61K in Q1 2022. 67 funds tracked by Wall St. Rank hold LENZ as of Q3 2023.

  • Erste Asset Management reported no remaining LENZ Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Erste Asset Management sold 1,700 LENZ Therapeutics shares in Q3 2023, an estimated $30.8K.
  • Erste Asset Management first reported a position in LENZ Therapeutics in Q1 2022 and held it in 6 quarters.
  • Erste Asset Management's LENZ Therapeutics position peaked at $61K in Q1 2022.
  • 67 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q3 2023.

Based on Erste Asset Management's 13F filing for Q3 2023, filed 26 Nov 2024.